27890470|t|sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension
27890470|a|Pulmonary hypertension (PH) is a chronic cardiopulmonary disorder that if left untreated, progresses rapidly and is ultimately fatal. The World Health Organization (WHO) has classified PH into 5 distinct groups according to pathophysiology, hemodynamic characteristics, and clinical presentation. Dysfunction in the nitric oxide (NO) pathway plays a key role in the pulmonary hypertension disease process, including in WHO Groups 2 and 3 PH. PH is associated with endothelial dysfunction, impaired synthesis of NO, and insufficient stimulation of the NO-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway, which reduces cGMP production. cGMP regulates vascular tone, cellular proliferation, inflammation, and fibrosis and its depletion can lead to a variety of abnormalities, including pulmonary vasoconstriction, impaired vascular remodeling, and in situ thrombosis. This review will examine a novel class of drugs called sGC stimulators which directly stimulate sGC independently of NO, leading to increased production of cGMP.
27890470	0	15	sGC stimulators	T103	UMLS:C3819023
27890470	30	39	riociguat	T103	UMLS:C2717561
27890470	47	55	groups 1	T038	UMLS:C2973725
27890470	60	84	4 pulmonary hypertension	T038	UMLS:C2363973
27890470	85	107	Pulmonary hypertension	T038	UMLS:C0020542
27890470	109	111	PH	T038	UMLS:C0020542
27890470	126	150	cardiopulmonary disorder	T038	UMLS:C0034072
27890470	223	248	World Health Organization	T092	UMLS:C0043237
27890470	250	253	WHO	T092	UMLS:C0043237
27890470	259	269	classified	T170	UMLS:C0008902
27890470	270	272	PH	T038	UMLS:C0020542
27890470	326	337	hemodynamic	T038	UMLS:C0019010
27890470	401	426	nitric oxide (NO) pathway	T038	UMLS:C1518332
27890470	451	473	pulmonary hypertension	T038	UMLS:C0020542
27890470	474	489	disease process	T038	UMLS:C0030660
27890470	504	507	WHO	T092	UMLS:C0043237
27890470	508	516	Groups 2	T038	UMLS:C3532326
27890470	521	525	3 PH	T038	UMLS:C3698136
27890470	527	529	PH	T038	UMLS:C0020542
27890470	549	572	endothelial dysfunction	T038	UMLS:C0856169
27890470	583	598	synthesis of NO	T038	UMLS:C1157570
27890470	636	716	NO-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway	T038	UMLS:C3271755
27890470	732	736	cGMP	T103	UMLS:C0018338
27890470	749	753	cGMP	T103	UMLS:C0018338
27890470	764	777	vascular tone	T038	UMLS:C0042396
27890470	779	801	cellular proliferation	T038	UMLS:C0596290
27890470	803	815	inflammation	T038	UMLS:C0021368
27890470	821	829	fibrosis	T038	UMLS:C0016059
27890470	873	886	abnormalities	T033	UMLS:C1704258
27890470	898	924	pulmonary vasoconstriction	T033	UMLS:C1867424
27890470	935	954	vascular remodeling	T038	UMLS:C3850148
27890470	960	978	in situ thrombosis	T033	UMLS:C1867429
27890470	997	1004	examine	T033	UMLS:C0332128
27890470	1022	1027	drugs	T103	UMLS:C0013227
27890470	1035	1050	sGC stimulators	T103	UMLS:C3819023
27890470	1076	1079	sGC	T103	UMLS:C1097411
27890470	1097	1099	NO	T103	UMLS:C0028128
27890470	1136	1140	cGMP	T103	UMLS:C0018338